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Abstract
Background: Patients with clear cell renal cell carcinoma (ccRCC) have few therapeutic options, as ccRCC is
unresponsive to chemotherapy and is highly resistant to radiation. Recently targeted therapies have extended
progression-free survival, but responses are variable and no significant overall survival benefit has been achieved.
Commercial ccRCC cell lines are often used as model systems to develop novel therapeutic approaches, but these do
not accurately recapitulate primary ccRCC tumors at the genomic and transcriptional levels. Furthermore, ccRCC exhibits
significant intertumor genetic heterogeneity, and the limited cell lines available fail to represent this aspect of ccRCC.
Our objective was to generate accurate preclinical in vitro models of ccRCC using tumor tissues from ccRCC patients.
Methods: ccRCC primary single cell suspensions were cultured in fetal bovine serum (FBS)-containing media or
defined serum-free media. Established cultures were characterized by genomic verification of mutations present
in the primary tumors, expression of renal epithelial markers, and transcriptional profiling.
Results: The apparent efficiency of primary cell culture establishment was high in both culture conditions, but
genotyping revealed that the majority of cultures contained normal, not cancer cells. ccRCC characteristically
shows biallelic loss of the von Hippel Lindau (VHL) gene, leading to accumulation of hypoxia-inducible factor
(HIF) and expression of HIF target genes. Purification of cells based on expression of carbonic anhydrase IX (CA9),
a cell surface HIF target, followed by culture in FBS enabled establishment of ccRCC cell cultures with an efficiency
of >80 %. Culture in serum-free conditions selected for growth of normal renal proximal tubule epithelial cells.
Transcriptional profiling of ccRCC and matched normal cell cultures identified up- and down-regulated networks
in ccRCC and comparison to The Cancer Genome Atlas confirmed the clinical validity of our cell cultures.
Conclusions: The ability to establish primary cultures of ccRCC cells and matched normal kidney epithelial cells
from almost every patient provides a resource for future development of novel therapies and personalized medicine
for ccRCC patients.
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Background
Renal cell carcinoma (RCC) is dominated by the clear
cell subtype (ccRCC), which makes up 70 % of all RCC
and has a poor prognosis [1]. Biallelic loss or inactiva-
tion of the von Hippel Lindau (VHL) gene via mutation,
deletion or promoter methylation occurs in up to 91 %
of sporadic ccRCC [2] and drives a strong pro-survival
and angiogenic program due to downstream hypoxia-
inducible factor (HIF) accumulation [3].
Cancer cell lines are used extensively to characterize
novel anti-cancer therapeutics, but such studies have
translated poorly from preclinical studies into clinically
useful drugs. Genome-wide analysis shows that ccRCC
cell lines have many more copy number alterations than
primary ccRCC tissues [4], and transcriptional profiles of
cell lines cluster separately from primary tumors [5]. In
addition, ccRCC exhibits significant intertumor genetic
heterogeneity [6, 7] and the limited cell lines available
fail to represent this aspect of ccRCC. A lack of patient-
matched normal cells further limits research due to the
consequent lack of appropriate controls for experiments
and drug screening efforts.
Recently researchers have developed methods for gener-
ation of primary tumor-derived cultures such as sphere-
forming or adherent cells from brain tumors [8, 9] or 3-D
organoids from colorectal cancers [10]. These primary
cultures are amenable to high-throughput assays and
other manipulations while simultaneously representing
more accurate preclinical models of the tumors from
which they are derived. We describe a protocol for effi-
cient generation of primary ccRCC and patient-matched
normal kidney epithelial cell cultures from ccRCC tissue
specimens, providing significant opportunities for devel-
opment of personalized medicine approaches for ccRCC
patients.
Materials and methods
Tumor collection and processing
ccRCC samples were obtained from the University
Health Network (UHN) and the Cooperative Health
Tissue Network from patients providing written consent
under UHN Research Ethics Board approval, protocol
#09-0828-T (Additional file 1: Table S1). ccRCC tumor
tissues were procured within 2–24 h of excision (CHTN
samples were shipped overnight from various sites in the
United States). Tissue was finely minced using a scalpel,
then incubated in a 5 to 10 mL volume of 1× Collagenase/
Hyaluronidase and 125 Units/mL DNase (Stem Cell
Technologies) with frequent pipetting at 37 °C for
two hours. Contaminating red blood cells were lysed
with ammonium-chloride/potassium (ACK) lysing buf-
fer (Gibco) and remaining undissociated tissue and
cell clumps were filtered out using 70 μm nylon
mesh. Dissociated cells were stained with trypan blue,
viable cells were counted and cells were either frozen
in 90 % fetal bovine serum (FBS)/10 % dimethylsulf-
oxide or placed into culture.
Cell culture
Cell suspensions were cultured in Iscove’s Modified
Dulbecco’s Medium (IMDM) with 10 % FBS or defined
serum-free media (DSFM). DSFM contained DMEM/
F12 +Glutamax, 1× B27 supplement (Gibco), 1× non-
essential amino acids (Sigma-Aldrich), 1× Lipid Mixture 1
(Sigma-Aldrich), 4 μg/mL Heparin, 1 mM N-acetyl cyst-
eine (Sigma-Aldrich), 10 mM HEPES, 10 ng/mL EGF
(Invitrogen), and 10 ng/mL bFGF (Invitrogen). Both cul-
ture conditions included 100 Units/mL penicillin, and
100 μg/mL streptomycin. 786–0 and A-498 cells were cul-
tured in IMDM with 10 % FBS, penicillin and strepto-
mycin. All cultured cells were plated at a density of at
least 5000 cells/cm2 in flasks coated with rat tail collagen
type IV (5 μg/cm2; BD Biosciences) and incubated at
37 °C, in 5 % CO2, 2 % O2. Cell culture media was re-
placed every three to four days and cultures were passaged
at confluence with 0.25 % Trypsin (Wisent) and split be-
tween 1:2 and 1:5 depending on growth rate. Cell cultures
were monitored for Mycoplasma infection (Mycoalert,
Lonza) and cell culture identity verification by short tan-
dem repeat profiling (AmpFLSTR® Identifiler®).
To determine doubling times, primary cell cultures
were seeded in collagen-coated 96-well plates in IMDM/
10 % FBS at 2500 and 5000 cells/well (6 technical repli-
cates each). 786–0 cells were seeded at a density of 300
cells/well. Plates were incubated in an IncuCyte ZOOM
incubator and 4 images/well were taken at each time
point. Growth curves based on cell confluence were
compiled using IncuCyte ZOOM software from which
estimates of doubling times were obtained.
VHL sequencing
DNA was extracted using the Qiagen QIAamp DNA
Mini kit. PCR for VHL was performed using primer se-
quences and melting temperatures in Additional file 2:
Table S2 and sequenced by Sanger sequencing. Mutations
were identified using FinchTV software.
Flow cytometry
Cells were suspended in Hank’s balanced salt solution
with 2 % FBS, blocked with 20 μg/ml mouse IgG on ice
for 10 min, then incubated on ice with anti-CD31-PECy7
(1:100; BD Biosciences), anti-CD45-PECy7 (1:100; BD
Biosciences) and anti-CA9-PE (Clone 303123, 1:10;
R&D Biosystems) for 30 min, washed, and resus-
pended in Hank’s + 2 % FBS with 1 μg/ml 4′,6-diamidino-
2-phenylindole (DAPI). Viable (i.e. DAPI-negative) CD45/
CD31-negative cells were sorted into CA9+ and CA9− pop-
ulations using a BD FACSAriaII cell sorter.
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Immunohistochemistry
Adherent cell lines were grown in chamber slides to 50–
90 % confluence, washed in PBS, fixed in 4 % parafor-
maldehyde for 15 min at 4 °C, and subsequently washed
and permeabilized in PBS with 0.1 % Tween. Cells were
then blocked with 0.5 % BSA, 5 % goat serum and 0.3 %
hydrogen peroxide, incubated with primary antibody for
30 min at room temperature, washed, and incubated
with a biotinylated goat anti-rabbit or goat anti-mouse
secondary antibody, as appropriate, at 1:1000 for 30 min
at room temperature. Cells were again washed, incu-
bated with 1:1000 streptavidin-HRP (BD Biosciences) for
30 min at room temperature, washed again, and in-
cubated with 3,3'-diaminobenzidine (DAB) for 5 to
10 min, as directed by the manufacturer (NovaRED
Peroxidase Substrate Kit; Vector Laboratories), counter-
stained with hematoxylin, dehydrated, and coverslipped
with histomount. Antibodies and dilutions were as
follows: Pan-Cytokeratin, 1:100 (AbCAM); PAX-8, 1:500
(Protein Tech Group); Alkaline Phosphatase, 1:50
(Millipore); Aquaporin1, 1:100 (Abcam); E-Cadherin, 1:100
(Cell Signaling).
Tumorigenicity in mice
One million VHLmut cells were re-suspended in 1:1 PBS/
standard growth factor Matrigel (BD Biosciences) and
injected under the renal capsule of male NOD/SCID/
IL2Rγ−/− mice. 5 mice were injected with each cell line.
Animal experimentation followed protocols approved by
the University Health Network Animal Care Committee.
After 10 weeks, mice were euthanized and tumors were
harvested, fixed in formalin, paraffin-embedded and sub-
jected to hematoxylin and eosin staining to assess histology.
Single Nucleotide Polymorphism (SNP) arrays
Genomic DNA was applied to Illumina Human Omni
Express-12 or Omni2.5–8 SNP arrays, hybridized as
instructed by the manufacturer, and scanned on the
iScan Reader (Illumina). SNP Array data was analyzed
with Nexus software using the SNP-FASST2 segmenta-
tion algorithm. Probe sets were centered to the median
for all samples. Linear systematic correction was applied
as follows: The bias values, including percent GC con-
tent and fragment length, were used to create a linear
model whose parameters were estimated using the least
squares method. The estimate was then subtracted from
the probe Log2Ratio to obtain the corrected probe
values. A minimum difference threshold of 25 % and a
p-value cutoff of 0.05 were used.
Transcriptional profiling
mRNA was extracted from snap-frozen tumor tissue and
from VHLmut and VHLwt cultures that were expanded
in 10 % FBS conditions at passages 2 to 5. mRNA was
isolated using a Qiagen RNeasy Kit and Poly-A enriched
mRNA libraries were prepared following the Illumina
TruSeq RNA Sample Preparation Kit v2 protocol. Li-
braries were sized on an Agilent Bioanalyzer, and their
concentrations were validated by qPCR. Equimolar
amounts of the eighteen different libraries were pooled,
and subjected to 51 cycles of single-read sequencing on
an Illumina HiSeq 2500 using Illumina V4 chemistry and
reagents. The mean number of reads/sample was 40.4 M
(min. 34.6 M, max 52.5 M). Reads were aligned to the
GRCh37 reference human genome, using Gencode V19
transcript models. Alignment was performed with
Tophat (v2.0.13), using default parameters and with the
Gencode V19 transcriptome index supplied. The median
percentage of aligned reads was 95.8 % (min 91.4 %, max
96.8 %). Gene expression levels were estimated with
Cufflinks (v.2.0.2) [11], using default parameters and the
Gencode V19 GTF file. All resulting cufflinks output
files were merged using a bespoke script written in R
(v.3.1.3). For differential expression analysis, a read
count matrix was generated with the Bioconductor pack-
age ‘GenomicFeatures’ (v1.18.7), using the UCSC hg19
“knownGene” transcripts table. Differential expression
was determined using limma (v3.22.7).
Gene set enrichment analysis
Three GSEA analyses were performed using the RNAseq
data: 1) Using the GSEA v2.2.1 PrerankedTool the
VHLmut and VHLwt signatures (Fig. 5a) were queried
against a ranked gene list of TCGA RNAseq data,
ranked based on adjusted p-values of ccRCC vs. adjacent
normal tissue [7]; 2) A gene set database obtained from
baderlab.org/GeneSets, which contains 14,082 gene sets
from KEGG, MSigDB, Reactome, and GO was queried
against a ranked list of the VHLmut vs. VHLwt RNAseq
data, ranked based on adjusted p-value; 3) MSigDB Col-
lection C5, consisting of 1454 GO gene sets was queried
against the patient tumor vs. VHLmut cells ranked gene
list (again ranked based on adjusted p-value). For the latter
two analyses, the outputs from GSEA were imported into
Cytoscape v3.2.0 and visualized using the Enrichment
Map plugin.
Results
Most unselected ccRCC cultures are not cancer cells
CcRCC specimens were processed into primary single cell
suspensions, cultured in 10 % FBS or defined serum-free
media (DSFM; see Methods) and incubated in 2 % oxygen
to improve cell growth and avoid DNA damage [12, 13].
Cells with an epithelial morphology that could be pas-
saged at least 4 times were consistently obtained (56.4 %
in DSFM and 71.8 % in FBS; n = 39). Eight primary
cultures with matched primary tumors and adjacent
normal tissues were genotyped using single nucleotide
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polymorphism (SNP) arrays and, surprisingly, 6 out of 8
cultures established in FBS and all cultures in DSFM had
a normal genotype (Additional file 10: Figure S1A). Se-
quencing of VHL in primary tumors and cultures verified
a patient tumor-matching VHL mutation in RCC22 cells
grown in FBS (Additional file 10: Figure S1B), while the
remaining lines did not recapitulate the patients’ tumor
VHL mutations.
To distinguish cancer vs. normal cells in subsequent
experiments, we sequenced the VHL gene in a cohort of
patients for whom cryopreserved viable single cell sus-
pensions were available. Once patients with sequence-
detectable mutations were identified, the cells were
thawed and cultured as before. Seven out of seven
DSFM cultures were VHL-wild-type (VHLwt) and only
one of seven cases grown in FBS (RCC130) was VHL-
mutant (VHLmut). Another FBS culture, RCC243 con-
tained a mixture of VHLmut and VHLwt cells at passage
two (Fig. 1a).
Purification of CA9-expressing cells facilitates establish-
ment of ccRCC cultures
VHL loss results in HIF accumulation and activation of
HIF target genes including carbonic anhydrase IX (CA9),
which is constitutively upregulated in VHL-mutant cells
and acts as a diagnostic biomarker in this disease [14, 15].
Fig. 1 Generation of patient-matched VHLmut and VHLwt cell cultures from primary ccRCC specimens. a RCC130 primary tissue (left) contained
a mixture of wild-type and mutant cells, and growth in 10 % FBS gave rise to a culture of pure VHLmut cells. RCC243 (right) contained a mixture
of wild-type and mutant cells, and growth in 10 % FBS gave rise to a culture that still contained a mixture wild-type and mutant cells. b Flow
cytometry profiles of CA9 expression in RCC22 VHLwt (left) and RCC22 VHLmut (right). CA9 is expressed on all RCC22 VHLmut cells, but not in
RCC22 VHLwt cells. c CA9+ and CA9− cells were sorted from RCC162 cells at passage 1 and placed back into culture, and VHL sequencing was
performed after 2 more passages. CA9− cells continued to give rise to a mixed population of mutant and wild-type cells, whereas CA9+ cells gave
rise to a culture of pure VHLmut cells. d CD45/CD31-negative cells were sorted from RCC323 primary tumor tissue single cell suspensions into
CA9+ and CA9− populations and cultured for 2 passages, then sequenced. CA9− cells gave rise to a culture of pure VHLwt cells, and CA9+ cells
gave rise to a culture of pure VHLmut cells
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Supporting this, RCC22 VHLmut cells expressed CA9,
while RCC22 VHLwt cells did not (Fig. 1b). To determine
whether this known ccRCC cell surface marker could be
used to select ccRCC cells present in mixtures of cancer
and normal cells, we purified CA9+ and CA9− cells from
cryopreserved primary single cell suspensions or early pas-
sage 10 % FBS cultures using fluorescence-activated cell
sorting, and (re)cultured them in 10 % FBS (Fig. 1c, d).
Cells were passaged twice before re-sequencing the VHL
gene. The efficiency of VHLmut cell culture establishment
increased to 37.5 % (6 out of 16 attempts) upon sorting of
CA9+ cells from early passage cultures, and to 84.6 % (11
out of 13 attempts) upon sorting of CA9+ cells from pri-
mary cell suspensions (Table 1). The CA9− population
gave rise to VHLwt cultures 75 % of the time vs. 66.7 % of
the time in early passage vs. primary cell suspensions, re-
spectively. We also established pure VHLwt cells 70.6 % of
the time when primary cell suspensions were plated dir-
ectly into DSFM without sorting. In 4 cases where VHLwt
cultures were not established by plating directly in DSFM,
they were established from purified CA9− cells. Once
established, VHLwt cells grew efficiently in both FBS and
DSFM conditions, and thus were transitioned to FBS con-
ditions once verified to be VHLwt by Sanger sequencing.
By contrast, VHLmut lines proliferated only in FBS.
VHLmut and VHLwt cells could not be distinguished
based on morphology (Additional file 10: Figure S2). Re-
sequencing at later passages (up to 20) verified that the
VHL status of both mutant and wild-type cultures was
maintained. Overall, we have successfully established 17
VHLmut ccRCC cell cultures, of which 16 have patient-
matched VHLwt cell cultures (Additional file 3: Table S3).
VHLwt cell cultures are renal proximal tubule epithelial cells
We next performed immunohistochemistry for renal
epithelial markers in VHLwt and VHLmut cultures. All
were positive for pan-Cytokeratin and PAX8 (Fig. 2), a
transcription factor expressed only in epithelial cells of
the adult kidney, in 98 % of ccRCCs [16], and in the thy-
roid gland and Müllerian duct derived tissues, but not
other tissues [17]. These results support the renal epi-
thelial origin of the VHLmut and VHLwt cultures.
VHLwt cells are also positive for proximal tubule
markers Alkaline Phosphatase [18] and Aquaporin1 [19]
Table 1 Efficiency of VHLmut and VHLwt primary culture establishment upon isolation of CA9+ and CA9- cells from early passage
cultures or primary single cell suspensions
Cells sorted at P0 to P2 Cells sorted from primary single cell suspension
Tumor ID Passage CA9+ CA9- CA9+ CA9- Unsorted (DSFM)
118c 0 pure T 50/50a pure T 50/50a no line
137c 0 mixture no line pure T pure N no line
138c 0 mixture no line pure T pure N no line
149c ND ND pure T pure N pure N
162c 0 pure T 50/50a ND ND 50/50a
171c 2 mixture pure N pure T pure N ND
183 1 pure N pure N ND ND pure N
200 ND ND mixture pure N no line
222c 0 mixture pure N pure T pure N pure N
243c 2 pure T mixture ND ND pure N
267 0 pure N pure N ND ND pure N
271c 0 pure T mixture pure T mixture pure N
291c 0 pure N pure N pure T no line ND
294 0 mixture pure N no line ND pure N
323c 0 pure T pure N pure T mixture pure N
364b ND ND pure T no line no line
373 0 mixture pure N ND ND pure N
400c 0 pure N pure N pure T pure N pure N
407c 0 pure T pure N ND ND pure N
6 of 16 ccRCC
cultures (37.5 %)
12 of 16 normal
cultures (75 %)
11 of 13 ccRCC
cultures (84.6 %)
8 of 12 normal
cultures (66.7 %)
12 of 17 normal
cultures (70.6 %)
T tumor, N normal, ND not done
aPatient had a germline VHL mutation, therefore normal cell cultures are heterozygous
bVHLmut cell line only was generated, n = 1
cVHLmut and VHLwt pairs were generated, n = 13
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(Fig. 3a) and negative for distal tubule markers E-
Cadherin and Calbindin1 (Additional file 10: Figure S3).
Furthermore, analysis of the expression of proximal and
distal tubule markers in RNAseq data generated from 6
pairs of VHLmut and VHLwt cells indicates consistently
higher expression of proximal tubule markers in VHLwt
cells (Fig. 3b), supporting their identity as proximal
tubule epithelial cells. VHLmut cells also express prox-
imal tubule markers, as expected [20].
Growth characteristics of VHLmut and VHLwt cells
To assess growth kinetics of VHLmut and VHLwt cul-
tures, growth curves were generated using an Incucyte
ZOOM live cell imaging apparatus. The doubling times of
Fig. 2 VHLmut and VHLwt cultures contain renal epithelial cells. VHLmut (top) and VHLwt (bottom) cultures stained positively with pan-Cytokeratin
(Pan-CK) and PAX8 antibodies, verifying their identity as renal epithelial cells. Three representative VHLmut/VHLwt pairs are shown. Scale bar = 100 μm
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7 VHLmut cultures averaged 130 h (range 44 to 219;
Additional file 4: Table S4). In contrast to VHLmut cultures,
the commercial cell line 786–0 had a doubling time of 16 h.
These 7 cultures have been passaged from 12 to 20 times
and have not yet shown signs of senescence. In contrast,
the growth of VHLwt cultures slows between passages 6
and 12, though significant expansion and cryopreservation
at early passage is possible. To assess tumorigenicity, 1 mil-
lion VHLmut cells were injected under the renal capsule of
five NOD/SCID/IL2Rγ−/− mice and 2 out of 4 VHLmut cul-
tures consistently generated tumor xenografts with ccRCC
histology within 10 weeks (Additional file 10: Figure S4).
Molecular analysis of VHLmut and VHLwt primary cultures
To assess genotype stability in vitro, we performed SNP
arrays on three VHLmut cultures that had reached 20
passages, two matched earlier passage VHLwt cultures, plus
their matched primary tumors and adjacent normal tissues.
Two commercially available ccRCC cell lines, 786–0 and
A-498 were also analyzed (Fig. 4). VHLwt cell cultures do
not exhibit gross genomic abnormalities. VHLmut cultures
match the copy number alterations (CNAs) of their paired
parental tumors, and display a few additional alterations
that were not obvious in primary tumors: RCC22mut and
RCC243mut have gain of chromosome 7, RCC243mut also
has loss of chromosome 4, and RCC364mut has 2 dele-
tions, one in chromosome 8 and one in chromosome 9. In
comparison, 786–0 and A-498 had considerably more
CNAs than primary ccRCCs.
We performed RNAseq on 6 VHLmut/VHLwt cell cul-
ture pairs grown in 10 % FBS at passage 2 to 5, as well
as RNA extracted from the matched primary tumor
Fig. 3 VHLwt cultures are renal proximal tubule epithelial cells. a VHLwt cultures stained positively for proximal tubule markers Alkaline
Phosphatase (ALPL) and Aquaporin1 (AQP1). Scale bar = 100 μm. b Expression values for proximal and distal tubule markers in VHLwt and
VHLmut cell cultures obtained from RNAseq data, indicating that both VHLwt and VHLmut cells express proximal but not distal tubule markers
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tissues. RNAseq data has been deposited in NCBI’s Gene
Expression Omnibus [21] and are accessible through GEO
Series accession number GSE74958. Upon unsupervised
clustering of gene expression profiles the tumor tissues
clustered discretely from the cultured cells, and the
VHLmut and VHLwt cultures formed discrete subclusters,
indicating distinct expression profiles within each sample
type (Additional file 10: Figure S5). 593 differentially
expressed protein-coding genes (cut-off of 2-fold and ad-
justed p-value ≤0.01) were identified between VHLmut
and VHLwt cell cultures (Fig. 5a). Genes differentially
expressed in VHLmut cells included hypoxia response
genes and genes related to metabolism, as expected
(Additional file 5: Table S5, Additional file 10: Figure S6).
Gene set enrichment analysis (GSEA) of the VHLmut and
VHLwt gene signatures against RNAseq data from
patient-matched primary tumor and adjacent normal tis-
sues generated by The Cancer Genome Atlas (TCGA) [7]
showed significant enrichment of the VHLmut signature
in ccRCC tumor tissues, and of the VHLwt signature in
normal adjacent kidney tissues, respectively (Fig. 5b).
To gain a better understanding of differentially expressed
networks in VHLmut vs. VHLwt cells, we also performed
GSEA of a compiled database of gene sets relating to
biological processes, molecular functions and pathways
[22] against a ranked gene list of our entire expression
dataset [23]. Results were visualized using Cytoscape
with the Enrichment Map plugin [22]. Only a few
networks were up-regulated in VHLmut cells, including
glycolysis and electron transport, hypoxia/oxygen response,
epigenetics/histone modification and bile acid and bile
salt transport (Fig. 6, Additional file 6: Table S6). The
top differentially expressed genes associated with each
of these networks are listed in Additional file 7: Table
S7. A larger number of pathways and networks were
enriched in VHLwt cells, including cell-cell and cell-
matrix interactions, focal adhesion and cytoskeleton
organization, epithelial and endothelial differentiation,
growth factor pathways such as TGFβ and TNF, glyco-
sylation, and RNA processing and transport (Additional
file 6: Table S6).
An analysis of differentially expressed genes between
VHLmut cell cultures and the matched tumors from
which they were derived revealed 4312 differentially
expressed genes (cut-off 2-fold and adjusted p-value
≤0.01; Additional file 8: Table S8). Interestingly, there
were many more genes lost in VHLmut cells as com-
pared to primary tumors (2781) than gained (1531). As
above, GSEA of gene ontology (GO) terms was per-
formed using the ranked gene list of the primary tumor
vs. VHLmut genes, and the results were again visualized
using the Cytoscape Enrichment Map plugin (Additional
file 10: Figure S7). Networks that were lost in VHLmut
cultures consisted almost entirely of networks associated
with immune responses, and mitochondrial respiration.
The only network found to be gained in the VHLmut
Fig. 4 Copy number profiles of VHLmut and VHLwt cultures and their matched tissues. Three VHLmut cultures that had reached passage 20 were
profiled using Illumina Human Omni2.5–8 SNP arrays. DNA samples obtained from the matching primary tumor and adjacent normal kidney
tissue were profiled in parallel, as well as two commercially available cell lines, 786–0 and A-498. For RCC22 and RCC243, the matched VHLwt
line was also profiled; RCC364 does not have a matched VHLwt line. Amplifications are shown in blue and deletions in red. VHLwt cell lines do
not display any gross genomic alterations, whereas VHLmut cell lines contain alterations matching the tumors from which they were derived.
786–0 and A-498 (bottom), have considerably larger numbers of alterations compared to primary tumors and RCC VHLmut cultures
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cultures as compared to the primary tumors was prolif-
eration (Additional file 9: Table S9).
Discussion
Our finding that unselected cultures derived from primary
ccRCC specimens contained predominantly genomically
normal epithelial cells was surprising and highlights the
importance of genotypic validation of newly established
cultures in comparison to the patient tissues from which
they are derived. Others have reported that normal cells
out-compete malignant cells in primary cancer cultures
[10, 24, 25], possibly explaining the poor efficiency of cell
Fig. 5 Differentially expressed genes in VHLmut vs. VHLwt cells. a Heatmap showing the 593 differentially expressed protein-coding genes between
VHLmut and VHLwt cells (cut-off of p≤ 0.01 and 2-fold change). b Gene set enrichment analysis (GSEA) plots of the 211 VHLmut-associated genes (left)
and 382 VHLwt-associated genes (right) in the TCGA ccRCC dataset. NES = normalized enrichment score; FDR q-val = false discovery rate q value. A
gene set is considered significant with FDR < 0.25
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line derivation from most solid tumors [26] where lines
can often be established, but cannot be maintained. Our
protocol establishes accurate VHLmut ccRCC cultures
that can be passaged at least 20 times. This method will
allow researchers to avoid use of extensively passaged lines
of uncertain provenance, instead enabling use of early pas-
sage, clinically relevant ccRCC cultures for basic studies.
The purification of ccRCC cells expressing CA9 in-
creased both culture accuracy and efficiency substan-
tially for samples bearing VHL mutations. This method
Fig. 6 Schematic of workflow to generate matched VHLmut and VHLwt cultures from surgically resected ccRCC samples. Tumor tissue that has
been surgically resected is digested with enzymes to generate a single cell suspension, as described in the Methods. A portion of the tissue is
used to extract DNA for VHL gene sequencing. The cell suspension can be viably frozen until sequencing results are obtained, if desired. An
aliquot of cells is cultured in DSFM to generate a VHLwt culture. Remaining cells are stained with antibodies to CD45 and CD31 to allow
exclusion of contaminating immune and endothelial cells, and the CA9+ and CA9- fractions are isolated by FACS and plated in media
containing FBS. We showed that when both methods for generating a VHLwt culture were performed, the success rate increased to 90 %
(9 out of 10 attempts; Table 1). After at least 2 passages, DNA is isolated from the cultured cells and sequenced to verify their identity as
VHLmut cells and VHLwt cells. Cultures should be monitored every few passages to ensure identity and VHL mutation status
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can be applied to any specimen yielding at least 1 mil-
lion viable cells upon processing, thus one limitation is
the inability to generate cultures from small specimens,
such as biopsies. While not all ccRCC tumors have a de-
tectable VHL mutation,VHL loss due to biallelic deletion
or epigenetic silencing occurs in many of these patients
[2]. While we have not formally tested CA9 sorting in
these patients, our method is likely also applicable in
these cases. Indeed, CA9 is expressed in the vast major-
ity (94 %) of ccRCC patients [15].
Our results indicated that cultures established in
DSFM were normal renal proximal tubule epithelial
cells, the presumed cell of origin for ccRCC [1]. The out-
growth of normal epithelial cells was surprising given
that these cells are not obviously present upon micro-
scopic examination of tumor tissues, leading us to con-
clude that tumor tissues contain rare residual normal
cells with a strong growth advantage over ccRCC cells in
DSFM. These culture conditions are remarkably similar
to conditions established decades ago for the culture of
proximal tubule cells from normal kidneys [27]. Interest-
ingly, our results indicate that DSFM culture conditions
that support other cancers like glioblastoma multiforme,
prostate cancer, and colorectal cancer [28] do not permit
ccRCC cell growth; when we transferred VHLmut cul-
tures from FBS to DSFM they failed to proliferate, sug-
gesting the intriguing possibility that identification of
essential growth factors for ccRCC cells could reveal
novel therapeutic targets. Importantly, the differential
growth requirements of VHLmut ccRCC cells and
VHLwt normal proximal tubule epithelial cells can be
exploited to consistently generate patient-matched nor-
mal cultures for virtually every cancer culture, even in
the absence of adjacent normal tissue. While these cells
senesce at passage 6 to 12, this could potentially be over-
come by immortalization with a human telomerase re-
verse transcriptase (hTERT) construct.
Primary VHLmut cultures had doubling times ranging
from 44 to >200 h, in striking contrast to the 786–0
doubling time of 16 h. This more accurately reflects the
heterogeneity and growth kinetics observed in patients
and primary xenografts. Cultures were readily established
from tumors of varying stages and grades (Additional file
1: Table S1) suggesting no bias for success from more ag-
gressive cancers. Two of four cultures tested to date gen-
erate xenografts with characteristic ccRCC clear cell
histology. The failure of some cultures to initiate tumors
in mice may be due to an insufficient cell dose, or to the
eight to ten week incubation period. In our experience
patient-derived xenografts initiated directly from primary
tissues require four to six months to engraft [29], thus lon-
ger incubation times may be required. This would further
indicate that our primary cultures are more reflective of
patients’ cancers than commercially available cell lines.
SNP array analyses indicated that, as shown by Beroukhim
et al. [4], the cell lines 786–0 and A-498 have a large num-
ber of CNAs. In our two SNP array experiments we saw a
single sample, RCC99 (Additional file 10: Figure S1) that
also had substantial CNAs, but this is not typical of
ccRCC, as seen in larger-scale genomic studies such as
that of Beroukhim et al. [4] and the TCGA [7]. Thus while
it is possible that cell lines such as 786–0 and A-498 were
derived from such samples, the more likely explanation is
that many genomic alterations are acquired during long-
term passage in culture. At passage 20 our VHLmut cul-
tures contained a small number of alterations that were
not apparent in their parent tumors, but they did not have
the extreme aneuploidy seen in commercially available
ccRCC cell lines [4]. This is likely related to their relatively
low passage number, and in part to their maintenance in a
low oxygen environment, which has been found to in-
crease plating efficiency and lifespan of cells in culture
[12], as well as lead to less DNA damage and fewer stress
responses [13]. The novel CNAs that were observed in
VHLmut cultures compared to their matched primary
tumors were concordant with common events in ccRCC
such as trisomy 7 [30], suggesting that clones with these
alterations may have been present at a subclonal level
within the primary tumors, or that cultures were derived
from a subclone that was not present in the portion of
tumor used for DNA analysis due to regional genetic
heterogeneity in ccRCC [31]. Future studies utilizing
cultures derived from multiple biopsies per patient may
provide valuable insights into biological differences be-
tween subclones. Alternatively, these alterations could
have been acquired during passage, suggesting that despite
our best efforts we did not entirely avoid the acquisition
of genomic alterations during culture, and supporting the
need to utilize in vitro models at early passage.
Transcriptional profiling identified differentially expressed
genes between VHLmut and VHLwt cultures. Our VHLmut
gene signature is highly enriched in patient ccRCC
samples analyzed by the TCGA and transcriptional
networks were identified that would be predicted as
a consequence of VHL loss: activation of the hypoxic
response and increased glycolysis due to HIF stabilization.
These results support the use of our VHLmut/VHLwt
paired cultures as representative models of ccRCC biology.
The observed increase in genes involved in electron trans-
port/oxidative metabolism, which has been shown to be
down regulated in other transcriptional analyses of ccRCC
[32] was initially unexpected, however, some of the genes
that are present in this network are in fact involved in
negative regulation of electron transport; for example,
the most significant gene in that network, NDUFA4L2
(see Additional file 7: Table S7) has been shown to be
involved in lowering mitochondrial oxygen consumption
and Complex I mitochondrial activity, causing a shift from
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mitochondrial respiration to anaerobic glycolysis [33].
Other genes in the network are associated with other
metabolic processes such as adipogenesis and glycogen
synthesis, in line with the fat and glycogen storage pheno-
type that is the hallmark of “clear cell” RCC [34]. In
addition, recent findings suggest that as ccRCC cell lines
adapt to in vitro culture they derive more of their meta-
bolic demands from oxidative metabolism than directly
isolated ex vivo cells [35]. We also noted a network of
epigenetics-related nodes, concordant with recent findings
that widespread deregulation of chromatin status occurs
in ccRCC due to activation of hypoxia-related pathways,
Fig. 7 Enrichment map of VHLmut vs. VHLwt gene expression profiles. To visualize networks and pathways differentially expressed between
VHLmut and VHLwt cell cultures, we performed gene set enrichment analysis, and visualized the results using the Cytoscape Enrichment Map
plugin, as described in the Methods. VHLmut related networks are shown in red (top) and VHLwt related networks are shown in blue (bottom)
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as well as mutations in epigenetic regulatory genes
[6]. Our observation that many networks are down-
regulated, including transcription and RNA process-
ing, is also consistent with observations that hypoxia
induces a signature of chromatin modifications and
global repression of transcription [36]. Additional path-
ways repressed in VHLmut cells include functions
related to normal epithelial biology and tissue homeos-
tasis, such as cytoskeleton organization, cell-cell interac-
tions, extracellular matrix organization and apoptosis,
whose loss likely plays a significant role in the malignant
behavior of ccRCC.
Comparison of transcriptional profiles between VHLmut
cells and their matched primary tumor specimens re-
vealed >4000 differentially expressed genes. At first
glance this suggests that the VHLmut cultures are not
representative of the primary tumors from which they
were derived at the transcriptional level. However, a dee-
per analysis of the differentially expressed genes in the
tumor tissues revealed that these were related primarily
to a wide range of immune functions, suggesting that
the expression of these genes was lost due to the pres-
ence of large numbers of infiltrating immune cells in the
tumor tissues that were not present in the cultures. Like-
wise, a higher expression of mitochondrial respiration-
associated genes in the tumor tissue likely also reflects
the presence of stromal cells within the tumor tissue that
do not have VHL mutations and thus maintain normal
levels of mitochondrial metabolism. Indeed, a recent
study in which an algorithm was developed to estimate
the fraction of stromal and immune cells in tumor sam-
ples from gene expression data [37] showed that, upon
analysis of gene expression data sets from ten tumor
types, ccRCC contained a particularly high level of im-
mune signature expression that correlated with the tumor
cellularity as assessed by DNA analysis. The predominant
network upregulated in VHLmut cultures compared to
the matched primary tissues was proliferation, which is
also not surprising given that the cultured cells are prolif-
erating in response to culture conditions, whereas the pro-
liferation index in ccRCC tumor tissues as defined by Ki67
staining is in general quite low (median 7.3 % in one study
of 176 patients) [38]. Thus overall, while a large number
of differentially expressed genes were identified between
tumor tissues and VHLmut cultures, the majority of these
were related to the loss of immune cells in the cultures,
and the stimulation of cell proliferation in vitro.
Conclusions
We have exploited the unique biology of ccRCC to
develop a protocol for the reproducible and accurate
generation of ccRCC and patient-matched normal prox-
imal tubule epithelial cell cultures (Fig. 7). Transcriptional
profiles recapitulate those of primary ccRCC tissues and
verify the expression of pathways known to be key compo-
nents of ccRCC cell biology. The high efficiency of cell
culture establishment means that large numbers of cultures
can be established from individual patients, allowing studies
to be performed that take into consideration the genetic di-
versity of patients. The ability to generate patient-matched
normal cultures from every patient provides a powerful tool
for exploring molecular and functional differences between
normal and cancer cells and provides ideal reagents for
screening for cancer-specific compounds. Our protocol
thus overcomes the severe limitations imposed by use of
commercial cell lines, and provides a unique resource for
the development of personalized therapeutic approaches
in a disease that is in great need of novel therapies.
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